1. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
- Author
-
Sandro Roberto De Araujo Cavallero, Ray Antonio Manneh Kopp, Fernando Sabino Marques Monteiro, Rodrigo Nogueira Fogace, Diogo Assed Bastos, Fabio A.B. Schutz, Helena Paes de Almeida Saito, Pamela Salman Boghikian, Pedro Luiz Serrano Usón, Fernando C. Maluf, Fernando Vidigal de Pádua, Evanius Garcia Wiermann, Sergio Aguiar, Felipe Moraes Toledo Pereira, Mouna Ayadi, Fábio Roberto Kater, Diogo Augusto Rodrigues da Rosa, Ricardo Saraiva de Carvalho, Fernando Nunes Galvão de Oliveira, Francisco Javier Orlandi, Vinicius Carreira Souza, and Silke Gillessen Sommer
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,030232 urology & nephrology ,MEDLINE ,Developing country ,Docetaxel ,Special Series: Genitourinary Malignancies in LMICs ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Orchiectomy ,Developing Countries ,business.industry ,Consensus conference ,Androgen Antagonists ,Guideline ,medicine.disease ,SPECIAL ARTICLES ,Castration-sensitive prostate cancer ,Prostatic Neoplasms, Castration-Resistant ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
PURPOSE International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advancements that were addressed in the Prostate Cancer Consensus Conference for Developing Countries for best-practice and limited-resource scenarios. METHODS A total of 24 out of 300 questions addressed staging, treatment, and follow-up for patients with mCSPC both in best-practice settings and resource-limited settings. Responses were compiled and presented in percentage of clinicians supporting each response. Questions had 4-8 options for response. RESULTS Recommendations for staging in mCSPC were split but there was consensus that chest x-ray, abdominal and pelvic computed tomography, and bone scan should be used where resources are limited. In both de novo and relapsed low-volume mCSPC, orchiectomy alone in limited resources was favored and in relapsed high-volume disease, androgen deprivation therapy plus docetaxel in limited resources and androgen deprivation therapy plus abiraterone in high-resource settings were consensus. A 3-weekly regimen of docetaxel was consensus among voters. When using abiraterone, a regimen of 1,000 mg plus prednisone 5 mg/d is optimal, but in limited-resource settings, half the panel agreed that abiraterone 250 mg with fatty foods plus prednisone 5 mg/d is acceptable. The panel recommended against the use of osteoclast-targeted therapy to prevent osseous complications. There was consensus that monitoring of patients undergoing systemic treatment should only be conducted in case of prostate-specific antigen elevation or progression-suggestive symptoms. CONCLUSION The treatment recommendations for most topics addressed differed between the best-practice setting and resource-limited setting, accentuating the need for high-quality evidence that contemplates the effect of limited resources on the management of mCSPC.
- Published
- 2021
- Full Text
- View/download PDF